The economics of osteoporosis prevention

Trends in Endocrinology and Metabolism

Volumn 8, Issue 6, 1997, Pages 236-239

  Torgerson, David J ^a   Gosden, Toby ^b   Reid, David M ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; HORMONE; VITAMIN D;

DRUG COST; FRACTURE; HEALTH ECONOMICS; HORMONE SUBSTITUTION; HUMAN; MEDICAL RESEARCH; MENOPAUSE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 0031214972     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(97)00059-3     Document Type: Review

References (41)

1. Barlow DH, Brockie JA, et al.: 1991. Study of general practice consultations and menopausal problems. BMJ 302:274-276.
2. Black D: 1995. Why elderly women should be screened and treated to prevent osteoporosis. Am J Med 98:2A-67S-2A-75S.
3. Black DM, Cummings SR, Karpf DB, et al.: 1996. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
4. Cauley J, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR: 1996. Bone mineral density and risk of breast cancer in older women. JAMA 17:1404-1408.
5. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR: 1995. Estrogen replacement therapy and fractures in older women. Ann Intern Med 122:9-16.
6. 3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327: 1637-1642.
7. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ: 1994. Effect of cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308:1081-1082.
8. Cheung AP, Wren BG: 1992. A cost-effectiveness analysis of hormone replacement therapy in menopause. Med J Aust 156:312-316.
9. Colditz GA, Hankinson SE, Hunter DJ, et al.: 1995. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1593.
10. Cooper C: 1993. Epidemiology and public health impact of osteoporosis. Baillieres Clin Rheumatol: Osteoporosis. 7:459-477.
11. Cummings SR: 1996. Quantification in prevention. Scand J Rheumatol 25(Suppl 103):101-107.
12. Cummings SR, Nevitt MC, Browner WS, et al.: 1995. Risk factors for hip fracture in white women. N Engl J Med 332:767-773.
13. Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M: 1992. HRT: an analysis of benefits, risks and costs. Br Med Bull 48:368-400.
14. Daly E, Vessey MP, Barlow D, Gray A, McPherson K, Roche M: 1994. Hormone replacement therapy in risk-benefit perspective. The modern management of the menopause; a perspective for the 21st Century. In Hammar M, Berg G. The Proceedings of the VII International Congress on the Menopause. London, Parthenon Publishing Group.
15. Dargent-Molina P, Favier F, Grandjean H, et al.: 1996. Fall related factors and risk of hip fracture: the EPIDOS prospective study. Lancet 348:145-149.
16. Felson D, Yuquing Z, Hannan MT, Keil DP, Wilson PWF, Anderson JJ: 1993. The effect of postmenopausal estrogen on bone density in elderly women. N Engl J Med 329:1141-1146.
17. Geelhoed E, Harris A, Prince R: 1994. Cost effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health 18:153-160.
18. Glüer C-C, Genant HK, Hans D, Langton C, International Quantitative Ultrasound Consensus Group: 1997. Quantitative ultrasound techniques for the assessment of osteoporosis: consensus on current status. J Bone Miner Res (in press).
19. Goddard M: 1992. The Cost Effectiveness of Hormone Replacement Therapy: A Review. Discussion Paper No. 73, University of York.
20. Hans D, Dargent-Molina P, Scholtt AM, et al.: 1996. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 348:511-514.
21. Heikinhimo RJ, Inkovaara JA, Harju EJ, et al.: 1992. Annual injection of Vitamin D and fractures of aged bones. Calcif Tissue Int 51:105-110.
22. Law E, Wald N, Meade TW: 1991. Strategies for prevention of osteoporosis and hip fracture. BMJ 303:453-459.
23. Liberman UA, Weiss SR, Broll J, et al.: 1995. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 1437-1443.
24. Lips P, Wilco C, Graafmans MS, Ooms ME, Bezemer PD, Bouter LM: 1996. Vitamin D supplementation and fracture incidence in elderly persons: a randomized controlled trial. Ann Intern Med 124:400-406.
25. Lufkin EG, Wahner HW, O'Fallon WM, et al.: 1992. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:1-9.
26. Mason J, Drummond M: 1995. Reporting guidelines for economic studies. Health Econ 4:84-94.
27. Nguyen T, Sambrook P, Kelly PJ, et al.: 1993. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 307: 1111-1115.
28. O'Neill TW, Marsden D, Silman AJ: 1995. Differences in the characteristics of responders and non-responders in a prevalence survey of vertebral osteoporosis. Osteoporos Int 5:327-334.
29. Torgerson DJ, Campbell MK: 1997. Unequal randomization can improve the economic efficiency of clinical trials. J Health Serv Res Policy (in press).
30. Torgerson DJ, Garton MJ, Donaldson C, Russell IT, Reid DM: 1993. Recruitment methods for screening programmes: Trial of an improved method within a regional osteoporosis study. BMJ 307:99
31. Torgerson DJ, Donaldson C: 1994. An economic view of high compliance as a screening objective. BMJ 308:117-119.
32. Torgerson DJ, Kanis J: 1995. The cost-effectiveness of preventing hip fractures in elderly women using vitamin D and calcium. Q J Med 88:135-139.
33. Torgerson DJ, Reid DM: 1997. The economics of osteoporosis and its treatment. Pharmacoeconomics 1997;11:126-138.
34. Torgerson DJ, Donaldson C, Garton MJ, Russell IT, Westland M, Reid DM: 1994. Population screening for osteoporosis: do non-attenders have a lower risk of osteoporosis? Osteoporos Int 4:149-153.
35. Torgerson DJ, Klaber-Moffett JK, Russell IT: 1996. Including patient preferences in randomized clinical trials. J Health Serv Res Policy 1:195-197.
36. Tosteson A, Weinstein M: 1991. Cost-effectiveness of hormone replacement therapy after the menopause. Baillieres Clin Obstet Gynaecol 5:943-959.
37. Tosteson A, Rosenthal DI, Melton LJ, et al.: 1990. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 113:594-603.
38. Weinstein M, Tosteson ANA: 1990. Cost effectiveness of hormone replacement therapy. Ann NY Acad Sci 592:162-173.
39. Weinstein MC: 1980. Estrogen use in postmenopausal women: costs, risks, benefits. N Engl J Med 303:308-316.
40. Weinstein MC, Schiff I: 1983. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 38:445-455.
41. Zelen M: 1979. A new design for randomized clinical trials. N Engl J Med 300:1242-1245.